Doping Issues and NPB - The Evolution of Drug Regulations

Historical Context of Drug Issues in NPB

Drug issues in NPB must be understood from two perspectives: performance-enhancing drugs (PEDs) and social drugs. Regarding PEDs, large-scale steroid contamination like MLB's has not been confirmed in NPB, though individual violation cases exist. On the other hand, regarding social drugs (stimulants, marijuana, etc.), incidents of active players being arrested have sent shockwaves through the baseball world. In 2016, a Giants player was arrested for stimulant use, and the inadequacy of NPB's overall drug countermeasures was severely questioned. This incident forced a shift from NPB's stance of treating drug problems as 'individual issues.' Building a systematic drug testing framework became urgent, and NPB embarked on fundamental institutional reform.

Find books about anti-doping on Amazon

Lessons from MLB's Steroid Era

From the late 1990s through the 2000s, MLB experienced the 'steroid era,' when performance-enhancing drugs including steroids were rampant. Behind the spectacular records of Mark McGwire and Sammy Sosa's home run race and Barry Bonds' record-breaking lay the shadow of doping. The 2003 BALCO scandal and the 2007 Mitchell Report exposed the severity of MLB's drug contamination. From this experience, MLB introduced a strict drug testing program and progressively strengthened penalties for violators. NPB aimed to build preventive drug countermeasures referencing MLB's lessons. However, compared to MLB, NPB's testing system remains relatively lenient, with differences in the frequency of random testing and the range of tested substances.

Building NPB's Anti-Doping Framework

NPB established its Anti-Doping Regulations in 2007 and began building a systematic drug testing framework. These regulations were designed as a unique framework adapted to professional baseball's characteristics while referencing World Anti-Doping Agency (WADA) standards. Testing is conducted through two tracks: random testing during the official season and regular testing during the off-season. Tested substances include anabolic steroids, growth hormones, stimulants, and diuretics. Penalties for confirmed violations are set progressively: a 20-game suspension for the first offense, a one-year suspension for the second, and permanent ban for the third. However, since NPB itself conducts the testing, ensuring independence has been identified as a challenge.

Books about MLB's steroid era are also helpful

Future Challenges and Outlook for Drug Regulation

While NPB's drug regulations have been steadily developed, many challenges remain for the future. First is ensuring testing independence. Under the current system, NPB handles both testing implementation and penalty decisions, and a transition to independent testing by a third-party organization is needed. Second is responding to new drugs. Next-generation substances that are difficult to detect with conventional testing, such as gene doping and selective androgen receptor modulators (SARMs), have emerged, requiring continuous updates to testing technology. Third is enhancing player education. Strengthening awareness activities regarding the risk of inadvertently ingesting prohibited substances (such as supplement contamination) is needed. For NPB to maintain trust as a clean sport, it must pursue both strengthened testing systems and player education in tandem.

References

  1. 日本野球機構「NPB アンチ・ドーピング規程」日本野球機構、2023-03-01
  2. 読売新聞「プロ野球と薬物問題 - 繰り返される不祥事の構造」読売新聞社、2022-11-10
  3. ESPN「MLB のステロイド時代を振り返る - ミッチェル報告書から 15 年」ESPN、2022-12-13
  4. 日本アンチ・ドーピング機構「日本のアンチ・ドーピング活動の現状と課題」JADA、2024-01-20